Sort   by:  
 Page size 
ProteomicsMuscle stems cell LC-MS - Common and Distinctive Functions of the Hippo Effectors Taz and Yap in Skeletal Muscle Stem Cell Function
Abstract Hippo pathway downstream effectors Yap and Taz play key roles in cell proliferation and regeneration, regulating gene expression especially via interaction with Tead transcription factors. To investigate their role in skeletal muscle stem cells, we analysed Taz in vivo and ex vivo in compar...
ORGANISM(S): Mus musculus (Mouse) 
2017-06-13 | PXD005751 | Pride
Taz Muscle Yap 
GenomicsThe Hippo tranducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation
The Hippo pathway effector YAP1 controls stem cell fate in epithelial tissues, but its role in stem cells of non-epithelial tissues, such as skeletal muscle, is poorly documented. Here we show that sustained YAP1 activity in mouse activated satellite cells in vivo induces rhabdomyosarcoma (RMS) rese...
ORGANISM(S): Homo sapiens 
2014-08-12 | E-GEOD-55186 | biostudies-arrayexpress
TranscriptomicsRole of Yes-Associated Protein 1 (YAP1) in rhabdomyosarcoma
Doxycycline-inducible YAP1 S127A-driven rhabdomyosarcoma (RMS) tumors, control skeletal muscle and regressed tumors following YAP1 normalization by doxycycline withdrawal were compared to determine the YAP1-regulated gene expression profile relevant to RMS formation. To characterize the role of YAP1...
ORGANISM(S): Mus musculus 
2014-08-12 | E-GEOD-47198 | biostudies-arrayexpress
GenomicsNational Cancer Institute Cancer Genome Characterization Initiative (CGCI)

The Office of Cancer Genomics at the National Cancer Institute is sponsoring a series of studies as part of the Cancer Genome Characterization Initiative (CGCI) to assess novel emerging sequencing technologies in cancer. The CGCI program includes comprehensive characterization of the genetic a...

phs000235.v3.p1 | EGA
GenomicsThe clonal and mutational evolution spectrum of primary triple negative breast cancers
Primary triple negative breast cancers (TNBC) represent approximately 16% of all breast cancers and are a tumour type defined by exclusion,for which comprehensive landscapes of somatic mutation have not been determined. Here we show in 104 early TNBC cases, that at the time of diagnosis these cancer...
EGAS00001000132 | EGA
GenomicsWhole genome sequencing - samples
Mutational landscapes of primary triple negative breast cancers - WGS
EGAD00001000115 | EGA
GenomicsRNA seq - samples
Mutational landscapes of primary triple negative breast cancers - RNA seq
EGAD00001000132 | EGA
GenomicsEGAD00010000148
tumour samples using Affymetrix Genome-Wide SNP6.0 arrays
EGAD00010000148 | EGA
GenomicsExome sequencing - samples
Mutational landscapes of primary triple negative breast cancers - Exomes
EGAD00001000113 | EGA
Sort   by:  
 Page size